Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage.

Trial Profile

Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms ASIM
  • Most Recent Events

    • 17 Jun 2017 Results (n=21) of US substudy, presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 21 Aug 2015 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top